Abstract:Objective: Osteosarcoma is the most common malignancy in the skeletal system; studies showed an important role of miRNAs in tumorigenesis, indicating miRNAs as possible therapeutic molecules. This study found abnormal hsa-miR-557 expression levels in osteosarcoma and tried to explore the potential function and the mechanism. Methods: Differential expression genes of osteosarcoma were analyzed using GSE28423 from the GEO database. Survival analysis of miRNAs was conducted with data obtained from the TARGET-OS database. STRING and miRDIP were used to predict target genes of hsa-miR-557; KRAS was then verified using dual-luciferase reporter assay. Expression of genes was detected by qPCR, and levels of proteins were detected by Western blot. The proliferation ability of cells was detected by CCK-8 and cell cycle analysis. Tumor formation assay in nude mice was used to detect the influence of osteosarcoma by hsa-miR-557 in vivo. Results: Analysis from the GEO and TARGET databases found 12 miRNAs that are significantly related to the osteosarcoma prognosis, 7 downregulated (hsa-miR-140-3p, hsa-miR-564, hsa-miR-765, hsa-miR-1224-5p, hsa-miR-95, hsa-miR-940, and hsa-miR-557) and 5 upregulated (hsa-miR-362-3p, hsa-miR-149, hsa-miR-96, hsa-miR-744, and hsa-miR-769-5p). CCK-8 analysis and cell cycle analysis found that hsa-miR-557 could significantly inhibit the proliferation of osteosarcoma cells. The tumor formation assay in nude mice showed that tumor sizes and weights were inhibited by hsa-miR-557 transfection. Further studies also proved that hsa-miR-557 could target the 3'UTR of KRAS and modulate phosphorylation of downstream proteins. Conclusion: This study showed that hsa-miR-557 could inhibit osteosarcoma growth both in vivo and in vitro, by modulating KRAS expression.

Mir-30a Inhibits Osteolysis by Targeting Runx2 in Giant Cell Tumor of Bone

Downregulation of Mir-223 and Mir-19A Induces Differentiation and Promotes Recruitment of Osteoclast Cells in Giant-Cell Tumor of the Bone Via the Runx2/TWIST-RANK/RANKL Pathway

MicroRNA-211 inhibits tumor growth and invasion through directly targeting RUNX 2 in osteosarcoma

MicroRNA-106b inhibits osteoclastogenesis and osteolysis by targeting RANKL in giant cell tumor of bone

MiR-126-5p Regulates Osteoclast Differentiation and Bone Resorption in Giant Cell Tumor Through Inhibition of MMP-13

Hsa-miR-557 Inhibits Osteosarcoma Growth Through Targeting KRAS

MiR-126-5p Regulates Osteolysis Formation and Stromal Cell Proliferation in Giant Cell Tumor Through Inhibition of PTHrP.

miR-30a-5p inhibits osteogenesis and promotes periodontitis by targeting Runx2

Smad3 is the key to transforming growth factor-β1-induced osteoclast differentiation in giant cell tumor of bone

MicroRNA-133a Inhibits Osteosarcoma Cells Proliferation and Invasion Via Targeting IGF-1R

MicroRNA-455-3p Inhibits Osteosarcoma Progression Via HSF1 Downregulation

MiR-302b Suppresses Osteosarcoma Cell Migration and Invasion by Targeting Runx2

Serglycin Induces Osteoclastogenesis and Promotes Tumor Growth in Giant Cell Tumor of Bone.

Mir-761 Inhibits Human Osteosarcoma Progression by Targeting CXCR1.

Mir-Oz Kegulates Osteoblast Apoptosis, Proliferation and Differentiation Through Targeted Inhibition of Runx2 in Osteoporosis Running Title: Role and Potential Mechanism of Mir-152 in Osteoporosis

Tumor-Suppressing Effects of Mir-429 on Human Osteosarcoma

MiR-29b Suppresses the Proliferation and Migration of Osteosarcoma Cells by Targeting CDK6.

Mir-664-3p Suppresses Osteoblast Differentiation And Impairs Bone Formation Via Targeting Smad4 And Osterix

miR-30-5p functions as a tumor suppressor and novel therapeutic tool by targeting the oncogenic Wnt/β-catenin/BCL9 pathway.

Regulatory effect of microRNA-34a on osteogenesis and angiogenesis in glucocorticoid-induced osteonecrosis of the femoral head.

Mir-139 Inhibits Osteosarcoma Cell Proliferation and Invasion by Targeting ROCK1.